<SEC-DOCUMENT>0001724521-24-000034.txt : 20240130
<SEC-HEADER>0001724521-24-000034.hdr.sgml : 20240130
<ACCEPTANCE-DATETIME>20240130081744
ACCESSION NUMBER:		0001724521-24-000034
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240129
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240130
DATE AS OF CHANGE:		20240130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcus Biosciences, Inc.
		CENTRAL INDEX KEY:			0001724521
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				473898435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38419
		FILM NUMBER:		24575943

	BUSINESS ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 694-6200

	MAIL ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rcus-20240129.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rcus-20240129</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001724521</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rcus-20240129.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-29</xbrli:startDate><xbrli:endDate>2024-01-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id663c04b78994401b19e8af556ffa4e7_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">January 29, 2024</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Arcus Biosciences, Inc.</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38419</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">47-3898435</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(State or Other Jurisdiction</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">of Incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(IRS Employer</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">3928 Point Eden Way</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Hayward</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94545</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">510</ix:nonNumeric>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">694-6200</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:40.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, Par Value $0.0001 Per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">RCUS</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div><div id="id663c04b78994401b19e8af556ffa4e7_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.01 Entry into a Material Definitive Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Amended and Restated Common Stock Purchase Agreement</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2024, Arcus Biosciences, Inc. (the &#8220;Company&#8221;) and Gilead Sciences, Inc. (&#8220;Gilead&#8221;) entered into a Third Amended and Restated Common Stock Purchase Agreement (the &#8220;A&amp;R Purchase Agreement&#8221;), which amends and restates in its entirety the Second Amended &amp; Restated Common Stock Purchase Agreement dated June 27, 2023 (the &#8220;Existing Purchase Agreement&#8221;). Pursuant to the A&amp;R Purchase Agreement, Gilead purchased from the Company 15,238,095 shares of the Company&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stock at a purchase price of $21.00 per share (the &#8220;2024 Gilead Financing&#8221;). All other terms of the Existing Purchase Agreement, including Gilead&#8217;s option to purchase additional shares from the Company, up to a maximum of 35% of the Company&#8217;s then-outstanding common stock, from time to time until July 13, 2025, remain unchanged.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated Investor Rights Agreement</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2024, the Company and Gilead entered into an Amended and Restated Investor Rights Agreement (the &#8220;A&amp;R Investor Rights Agreement&#8221;), which amends and restates in its entirety the Investor Rights Agreement dated May 27, 2020, as amended on October 11, 2022 (as previously amended, the &#8220;Existing Investor Rights Agreement&#8221;). Pursuant to the A&amp;R Investor Rights Agreement, and in connection with the 2024 Gilead Financing, (i) Gilead has the right to designate up to three individuals to be appointed to the Company&#8217;s board of directors (the &#8220;Board&#8221;), (ii) Juan Jaen, Ph.D. and Jennifer Jarrett would resign from the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and (iii) the Company agreed to establish a Science Committee and any director appointed by Gilead having an advanced scientific degree shall be a member of such Science Committee. All other terms of the Existing Investor Rights Agreement, remain unchanged.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment No. 3 to Option, License and Collaboration Agreement</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2024, the Company and Gilead also entered into Amendment No. 3 (&#8220;Amendment No. 3&#8221;) to the Option, License and Collaboration Agreement, dated May 27, 2020, as amended on November 17, 2021 and May 12, 2023 (as previously amended, the &#8220;OLCA&#8221;). Amendment No. 3, among other things, (i) makes various modifications to the program governance structure, (ii) requires Gilead to pay the $100,000,000 option continuation payment due on the fourth anniversary of the OLCA, and (iii) provides that the Company will operationalize and fund a Phase 3 study to evaluate quemliclustat in pancreatic cancer in addition to certain other activities. In connection with Amendment No. 3, the Company and Gilead have reprioritized the joint domvanalimab development program to focus on advancing and potentially accelerating their Phase 3 studies, STAR-121 (lung cancer) and STAR-221 (gastrointestinal cancer), and are discontinuing enrollment in the Phase 3 ARC-10 study evaluating domvanalimab plus zimberelimab compared to pembrolizumab monotherapy in front-line, locally advanced or metastatic, PD-L1-high non-small cell lung cancer. No changes to the safety and efficacy profile of domvanalimab and zimberelimab have been observed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing is only a brief description of the material terms of the A&amp;R Purchase Agreement, A&amp;R Investor Rights Agreement and Amendment No. 3 and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to each agreement, which will be filed as exhibits to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023.</span></div><div id="id663c04b78994401b19e8af556ffa4e7_78"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.02 Unregistered Sales of Equity Securities.</span></div><div style="margin-bottom:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth in Item 1.01 above related to the Gilead Financing is incorporated by reference here. The shares were sold to Gilead pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and were sold to one entity that is an accredited investor.</span></div><div id="id663c04b78994401b19e8af556ffa4e7_73"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2024 (i) Dr. Jaen and Ms. Jarrett resigned from the Board and (ii) following such resignations, the Board appointed Johanna Mercier to the Board as a Class II director. Dr. Jaen and Ms. Jarrett&#8217;s resignations are not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Mercier is the Chief Commercial Officer of Gilead and is being appointed pursuant to Gilead&#8217;s rights under the A&amp;R Investor Rights Agreement and will not receive any compensation for her service as a member of the Board. The Company expects to enter into its standard form of indemnification agreement with Ms. Mercier.</span></div><div id="id663c04b78994401b19e8af556ffa4e7_68"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01 Other Events.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2024, the Company issued a press release announcing various updates regarding its anti-TIGIT clinical development program. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div id="id663c04b78994401b19e8af556ffa4e7_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991.htm">Press release dated January 29, 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL Document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div><div id="id663c04b78994401b19e8af556ffa4e7_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:46.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: January 30, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Terry Rosen, Ph. D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terry Rosen, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</span></div><div style="margin-top:0.72pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id2e63384a3334365b69be7bfc71ff041_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:58px;margin-bottom:5pt;vertical-align:text-bottom;width:179px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">                                            </font><img alt="image_1.jpg" src="image_1.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:115px"></div><div><font><br></font></div><div style="padding-left:8.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:50.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.073%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Contacts&#58;</font></div><div style="padding-left:317.75pt;padding-right:2.75pt;text-indent:-315pt"><font><br></font></div><div style="padding-left:317.75pt;padding-right:2.75pt;text-indent:-315pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jacquie Ross, Investors</font></div><div style="padding-left:317.75pt;padding-right:2.75pt;text-indent:-315pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">investor_relations&#64;gilead.com</font></div><div style="padding-left:317.75pt;padding-right:2.75pt;text-indent:-315pt"><font><br></font></div><div style="padding-left:317.75pt;padding-right:2.75pt;text-indent:-315pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meaghan Smith, Media</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">public_affairs&#64;gilead.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Arcus Contacts&#58;</font></div><div style="padding-left:317.75pt;padding-right:2.75pt;text-indent:-315pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pia Eaves, Investors<br></font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">peaves&#64;arcusbio.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, (617) 459-2006</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Holli Kolkey, Media</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">hkolkey&#64;arcusbio.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (650) 922-1269</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GILEAD  AND  ARCUS  ANNOUNCE  AMENDED  COLLABORATION  AND  EQUITY INVESTMENT    </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Investment Reinforces Companies&#8217; Conviction in TIGIT Pathway and Provides Opportunity to Accelerate the Anti-TIGIT Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8211; Additional Equity Investment of $320M, Raising Gilead&#8217;s Ownership Stake in Arcus to 33% &#8211;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8211; Amendment Provides Gilead with One Additional Seat on the Arcus Board &#8211;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foster City, Calif., &#38; Hayward, Calif., January 29, 2024 &#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (Nasdaq&#58; GILD) and Arcus Biosciences, Inc. (NYSE&#58; RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The equity investment and collaboration amendment enable accelerated growth of the companies&#8217; joint development programs that span multiple indications. Additionally, Johanna Mercier, Chief Commercial Officer at Gilead Sciences, will join the Arcus Board, bringing Gilead&#8217;s total director designees to three. The amendment also includes governance enhancements enabling streamlined decision-making and reflecting the continued growth of the collaboration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;This amendment allows Gilead to accelerate the domvanalimab program and enables Arcus to focus on progressing multiple pipeline assets, including both Gilead-optioned and non-optioned programs,&#8221; </font><font style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#8220;We look forward to strengthening our collaboration as we explore the collective power of our cross-portfolio combinations to help transform how cancer is treated.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead and Arcus have reprioritized the joint domvanalimab development program to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">focus on advancing and potentially accelerating the Phase 3 studies STAR-121 (lung cancer) and STAR-221 (gastrointestinal cancer)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> which are both </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expected to be fully enrolled by year-end. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This prioritization focuses on domvanalimab-containing regimen research in areas where it may have significant impact in combination with chemotherapy and in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">settings with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">high unmet need through all-comer study designs. The companies also plan to initiate STAR-131, a new registrational Phase 3 lung cancer study that includes the domvanalimab plus zimberelimab regimen.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> This prioritization reflects the companies&#8217; continued conviction in the TIGIT pathway and the Fc-silent design of domvanalimab, which has the potential for differentiation in both efficacy and safety.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gilead Sciences, Inc.  333 Lakeside Drive  Foster City, CA  94404  USA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">www.gilead.com</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">phone</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> 650 574 3000  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">facsimile</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> 650 578 9264</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Since the inception of our partnership with Gilead in 2020, the companies have moved increasingly closer in all aspects of our research and development efforts,&#8221; said Terry Rosen, Ph.D., Chief Executive Officer, Arcus. &#8220;This investment and prioritization enable both companies to leverage their respective strengths and focus on efficiently advancing novel combinations that have the potential to change the landscape of cancer treatment. The additional investment by Gilead, which extends our cash runway into 2027, will enable us to fund our Phase 3 studies of quemliclustat in pancreatic cancer and AB521 in kidney cancer, as well as to begin preparation for our first potential product approvals.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additional changes during this prioritization will include discontinuing further enrollment in the Phase 3 ARC-10 study evaluating domvanalimab plus zimberelimab compared to pembrolizumab monotherapy in first-line locally advanced or metastatic PD-L1-high NSCLC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The discontinuation of the ARC-10 study is based on strategic prioritization to advance and potentially accelerate the Phase 3 studies STAR-121 and STAR-221, which have the potential to address a higher unmet need for patients with lung and gastrointestinal cancers.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead and Arcus are grateful to the patients and investigators who have made the choice to participate in ARC-10, which will continue to generate data and insights that will be shared at future scientific conferences. Patients currently enrolled in ARC-10,</font><font style="background-color:#ffffff;color:#365f91;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or who consented prior to January 29, 2024, and choose to enroll in the study, may continue their treatment and be monitored according to the study protocol. No changes to the safety and efficacy profile of domvanalimab and zimberelimab have been observed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Also, under the terms of the amended collaboration agreement, the planned Phase 3 first-line study in pancreatic cancer evaluating the investigational small molecule CD73 inhibitor quemliclustat will become an Arcus independent study.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Domvanalimab, zimberelimab and quemliclustat are investigational molecules. Neither Gilead nor Arcus has received approval from any regulatory authority for any use of these molecules, and their safety and efficacy for the treatment of lung, gastrointestinal and pancreatic cancers have not been established. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About Domvanalimab</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Domvanalimab is the first Fc-silent investigational monoclonal antibody in pivotal trials which was designed to block and bind to the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), a protein on immune cells that acts as a brake on the immune response. Cancer cells can exploit TIGIT to avoid detection by the immune system. By binding to TIGIT, domvanalimab is designed to free up immune activating pathways and activate immune cells to attack and kill cancer cells. Domvanalimab has demonstrated complete target coverage on all TIGIT-expressing immune cells in the blood of patients.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Domvanalimab is being evaluated in three registrational Phase 3 studies across lung and gastrointestinal cancers, including&#58; (1) STAR-121, evaluating domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy in first-line all comer NSCLC regardless of PD-L1 expression levels&#59; (2) STAR-221, evaluating domvanalimab plus zimberelimab and chemotherapy versus nivolumab plus chemotherapy in first-line locally advanced, unresectable or metastatic gastric, esophageal and gastro-esophageal junction adenocarcinomas&#59; and (3) PACIFIC-8, being operationalized by AstraZeneca, evaluating domvanalimab plus durvalumab in unresectable Stage 3 NSCLC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About Zimberelimab</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Zimberelimab is an anti-programmed cell death protein-1&#160;(PD-1) monoclonal antibody that binds PD-1, with the goal of restoring the antitumor activity of T cells. As a differentiated next-generation, fully </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">human antibody, zimberelimab has demonstrated high affinity, selectivity and potency in various tumor types.</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Guangzhou Gloria Biosciences Co. Ltd., who holds commercialization rights for zimberelimab in greater China, has obtained approval for zimberelimab as the first and only anti-PD-1 antibody to treat recurrent or metastatic cervical cancer (September 2023). Additionally, in China, zimberelimab is approved to treat relapsed or refractory classical Hodgkin's lymphoma (August 2021). Zimberelimab is not approved for any use in the U.S. or other regions outside of China. Gloria conducts its development and commercialization activities independent of Arcus and Gilead.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About Arcus Biosciences</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a&#47;A2b receptor), HIF-2a, CD39 and AXL. For more information about Arcus Biosciences&#8217; clinical and preclinical programs, please visit</font><font style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.arcusbio.com</font><font style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About Gilead Sciences</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Arcus Forward-Looking Statements </font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the statements regarding&#58; the initiation of new studies and continuation or discontinuation of existing studies and indications&#59; the ability of Arcus to advance its pipeline&#59; Arcus&#8217;s expectations regarding the completion of enrollment of STAR-121 and STAR-221 in 2024&#59; Arcus&#8217;s expectations regarding the extension of its cash runway into 2027&#59; and the potential of domvanalimab-containing regimens to be differentiated and potentially transformative in the treatment of certain cancers. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause our actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to&#58; dependence on the collaboration with Gilead for the successful development and commercialization of Arcus&#8217;s investigational products, including domvanalimab and zimberelimab&#59; difficulties associated with the management of the collaboration activities or expanded clinical programs&#59; the emergence of new or unexpected adverse events or unfavorable results from ongoing or future clinical trials with domvanalimab, zimberelimab or quemliclustat&#59; the inherent uncertainty associated with pharmaceutical product development and clinical trials&#59; delays in Arcus&#8217;s clinical trials due to difficulties or delays in the regulatory process, enrolling subjects or manufacturing or supplying product for such clinical trials&#59; and changes in the competitive landscape for Arcus&#8217;s programs. Risks and uncertainties facing Arcus are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">described more fully in the &#8220;Risk Factors&#8221; section of Arcus&#8217;s most recent periodic report that has been filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Gilead Forward-Looking Statements</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that Gilead may not realize the potential benefits of amended collaboration and investment agreement with Arcus or its other investments in oncology&#59; difficulties or unanticipated expenses in connection with the collaboration and the potential effects on Gilead&#8217;s revenues and earnings&#59; the risk that Gilead&#8217;s investment in Arcus will lose value for any number of reasons&#59; the ability of the parties to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials, including those involving domvanalimab, zimberelimab and&#47;or quemliclustat (such as STAR-121, STAR-131, STAR-221 and PACIFIC-8)&#59; uncertainties relating to regulatory applications for these and other candidates and related filing and approval timelines&#59; Gilead&#8217;s ability to receive regulatory approvals for such candidates in a timely manner or at all, and the risk that any such approvals may be subject to significant limitations on use&#59; the possibility that the parties may make a strategic decision to terminate the collaboration at any time, or to discontinue development of programs for indications currently under evaluation and as a result, such programs and&#47;or indications may never be commercialized&#59; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">###</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The Arcus name and logo are trademarks of Arcus Biosciences, Inc., and Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">For more information about Gilead, please visit the company&#8217;s website at </font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.gilead.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">, follow Gilead on X (&#64;GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rcus-20240129.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:89fd0c75-2350-42fa-a214-b619caea4d11,g:07cb59c3-1230-498b-9dc2-685866fef896-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rcus="http://arcusbio.com/20240129" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://arcusbio.com/20240129">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20240129_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20240129_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20240129_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://arcusbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>rcus-20240129_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:89fd0c75-2350-42fa-a214-b619caea4d11,g:07cb59c3-1230-498b-9dc2-685866fef896-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://arcusbio.com/role/Cover" xlink:type="simple" xlink:href="rcus-20240129.xsd#Cover"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_a25c49e9-9389-4679-a591-6e18c260dd73" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_7afd5d11-5cba-4e80-91df-55b28b8b86e3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_a25c49e9-9389-4679-a591-6e18c260dd73" xlink:to="loc_dei_DocumentInformationTable_7afd5d11-5cba-4e80-91df-55b28b8b86e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_415ddb66-c31e-4ea0-ab68-27e074746cef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a25c49e9-9389-4679-a591-6e18c260dd73" xlink:to="loc_dei_DocumentPeriodEndDate_415ddb66-c31e-4ea0-ab68-27e074746cef" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>rcus-20240129_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:89fd0c75-2350-42fa-a214-b619caea4d11,g:07cb59c3-1230-498b-9dc2-685866fef896-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentPeriodEndDate_a051e213-89ec-473c-bab9-37ebcea2825c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_d7b923db-803e-48c7-9f9c-6ef6ee39c615_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_ec089c0b-2dcd-488e-8a8c-20ba39d8a9fd_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4ea0f305-52ef-4588-9b14-2c59da3baa82_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1b29b7eb-f187-4380-97b0-905cceff9c7d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_04a04ecf-cc6b-4e27-84fe-4c10497a85bb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6587a990-a3bd-4e2b-b625-bc2ca4507784_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b2ef34c7-3fe9-4b05-a696-cef7d2e64281_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_aa167e26-708f-4c01-8781-ec657f8625c8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_0ed48494-9688-4a9c-bf53-97bfffd6cf76_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_fe1a2180-d685-4fa4-bf2a-ce331a109fc1_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2d5ac04c-de1b-463e-8688-68405d34feb9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_663bedbc-026c-4fa8-94ab-08ffc041c560_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_46ffbc9f-8364-4ce7-8a7e-a0d10bc8a4f8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c72aca1c-0e41-478c-a23a-6175539d3ddb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_c2be09e4-9d06-41fa-a81c-918dd0c90f3b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_07aa4f62-24e7-4278-916d-3924f6b76153_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4c900f5b-07a3-4200-a8ca-0853d6e10584_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cd3e0e96-4b4d-4be5-970f-19f2be23ed86_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8a6828f5-818d-4eb9-a9b9-38a9358de02d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_4451c2f6-a998-4b46-b99a-e2e70503f3ee_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9cd2fbe3-93b8-44fe-9cc1-8c7f95c2dae7_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2a095258-f6a7-4e37-9074-c3f28c44089e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_171d50d7-5b74-4f8f-be86-c1c645b01ff8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_49d3d0f3-72f9-4eb7-b283-f099d0e25f0f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>rcus-20240129_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:89fd0c75-2350-42fa-a214-b619caea4d11,g:07cb59c3-1230-498b-9dc2-685866fef896-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://arcusbio.com/role/Cover" xlink:type="simple" xlink:href="rcus-20240129.xsd#Cover"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b8cd085a-f719-4596-8d04-fb8a22562415" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_DocumentType_b8cd085a-f719-4596-8d04-fb8a22562415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_37d40716-23f2-43c8-86ea-2e0d31b542cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_DocumentPeriodEndDate_37d40716-23f2-43c8-86ea-2e0d31b542cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_efe5db35-3304-440f-9217-da45cbe130c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_EntityRegistrantName_efe5db35-3304-440f-9217-da45cbe130c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7da8db28-64c3-4670-a49a-b4cf2cae01be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7da8db28-64c3-4670-a49a-b4cf2cae01be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9d17ea3a-bc86-44a1-9dee-43ddcecf725a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_EntityFileNumber_9d17ea3a-bc86-44a1-9dee-43ddcecf725a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6338d050-eaf2-45f6-ae8e-babafad34e76" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_EntityTaxIdentificationNumber_6338d050-eaf2-45f6-ae8e-babafad34e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ce301acb-441a-49da-9fd1-0e221c3fbb8b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_EntityAddressAddressLine1_ce301acb-441a-49da-9fd1-0e221c3fbb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6cf5707d-4f3d-4985-8f52-1e2a36a60fd5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_EntityAddressCityOrTown_6cf5707d-4f3d-4985-8f52-1e2a36a60fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6efd78f2-f0aa-4c2a-8be9-efd866d3f88b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_EntityAddressStateOrProvince_6efd78f2-f0aa-4c2a-8be9-efd866d3f88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e5e91cb7-d34e-449d-9590-ae105f1dfe9c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_EntityAddressPostalZipCode_e5e91cb7-d34e-449d-9590-ae105f1dfe9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_101a5f1e-eb42-4036-8eaa-f9460d737f2f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_CityAreaCode_101a5f1e-eb42-4036-8eaa-f9460d737f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_63494522-7468-410a-8393-ce06b59e19ee" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_LocalPhoneNumber_63494522-7468-410a-8393-ce06b59e19ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_8c582750-6d99-43b9-ab8a-b230f78eb4bd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_WrittenCommunications_8c582750-6d99-43b9-ab8a-b230f78eb4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_22746c6b-260d-4152-8e7c-e043407ef3d6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_SolicitingMaterial_22746c6b-260d-4152-8e7c-e043407ef3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_1f685e36-0ed1-4372-b730-2befd074b305" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_PreCommencementTenderOffer_1f685e36-0ed1-4372-b730-2befd074b305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f4d05868-7b3d-40fe-91c8-c544d37af086" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f4d05868-7b3d-40fe-91c8-c544d37af086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_19994571-7d6d-46fc-8913-c55ab8893651" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_Security12bTitle_19994571-7d6d-46fc-8913-c55ab8893651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ee37dc03-6aa8-41fb-a0db-8f8f6973d5c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_TradingSymbol_ee37dc03-6aa8-41fb-a0db-8f8f6973d5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_97abc7c7-227e-4431-a652-2b8d919c63aa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_SecurityExchangeName_97abc7c7-227e-4431-a652-2b8d919c63aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4a1ffb93-1a09-42af-9b32-b4c0d93a7f43" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_EntityEmergingGrowthCompany_4a1ffb93-1a09-42af-9b32-b4c0d93a7f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0e6336fe-6d9b-4b50-9ffc-0e13f6323c23" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_AmendmentFlag_0e6336fe-6d9b-4b50-9ffc-0e13f6323c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_95167e26-b05d-4521-8af4-b54f8854c562" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_EntityCentralIndexKey_95167e26-b05d-4521-8af4-b54f8854c562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_7afd5d11-5cba-4e80-91df-55b28b8b86e3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c1011b0c-17d4-45b6-be05-c57dacb4fc0b" xlink:to="loc_dei_DocumentInformationTable_7afd5d11-5cba-4e80-91df-55b28b8b86e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_a25c49e9-9389-4679-a591-6e18c260dd73" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_7afd5d11-5cba-4e80-91df-55b28b8b86e3" xlink:to="loc_dei_DocumentInformationLineItems_a25c49e9-9389-4679-a591-6e18c260dd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_415ddb66-c31e-4ea0-ab68-27e074746cef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a25c49e9-9389-4679-a591-6e18c260dd73" xlink:to="loc_dei_DocumentPeriodEndDate_415ddb66-c31e-4ea0-ab68-27e074746cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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M? E[^_JA&W+J=(I_P-HB53&=(((YH#\X/-#)'@>.0-S*6(VO_YJ1D1$ZSVP
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M+G/-J+^XF'BV,0G#P\-1D:^Z[?!?4CY=?V:3^?JU&ZQ0N#^0L$EIMVZ36:2
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-S0    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
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ME9E.7M\8F2$HPKIB3B^UG@$F]R?V$V3_SY'/18HH&UO@C]W&PG2R7LHAO+O
M))V$0IPCN;1+T# O1R-=B%[\:U/!;1I/5PDD3 8D=K]#3&7C!&,#S/ZGR.>T
M$MLE"()23>X-%/,[00ZTF)9,3!K0 V\51/U700A\@#IY$.[==6AP%PB2<19Z
MN_/00UZ+7FL99"7*YQ?T8A$-&1:1K+>*LN]'EE._[\Q?H)UQ^]8QHOHG*RFQ
MZ,,)ZJQ0^>MSX;[<"*OD.9C1OR4N(Y"IV6/[5R&]2UA9N09I^2NEE1$T3S:D
MNM=>R@"8ZWZD!6Z??B7GTN[G9+A1?,!V]2]^:X&+_ 7*:3$(\&KHZ1R0RZE#
MALP<9 79 2)!N-4SH&NO\I)O4XA8HO+6[N0"+;#"OD;<+Z+1WXNP;H9[<"/J
M[0[D]7%14CX2)'4C2 &-/ZY<8(T&&AE&^YQW!7X+ATWE!YW^DMQ7*RD[!DI*
MI@T5176>Y/9%]01@M[NM1SK@X'WEHIAX$Y>(QN)P&R_"#$5OVBWH%1J9)YG8
M[X]_/+7(P?OKR.PE]HY-#PBD01"-AT71.#H3@35P/(TU0 DNX07M04XV?D-C
M0D.EWCI.84R!N=B&AODA&L!Q5EJS03XG*#!I=9CQL]KB2 '_4QKP^Q:0TGUE
MC'[PD+*9[C^6G5J4ES=E-[Q/@Z?DW\*/G;0KE4]IJ6\?F+1'H'R6.=CZIE 8
M%*Y]'3*\T<*(VC]#(_1VH-%[*G^^'YG#A873G>@X;H)O;DL2J(,V],9O.CGE
M1')G0J/\]+Y)#%D,4(813H=WE]UWGSFHU.D_!"[P"R"OMLATT-^B%'BMC%4.
MVFWP27 %)R-?9MPV \US"ARB<@PZG<]!RA$KB<,=Q:PVP:U]"MTXOKC8MV]A
MF8_9???)@\A%IP', 0-.V6OH4%\)U<E0KKZ&%?6;2MGZ1N@.K$TS39'E$_M_
MT,$&6M!9GQ'*UXZ! E:H/QP-875D0I&9-E96XY9/DV_*07E@HMHRM5D9LK$:
M!3P[--76_1C*J@(C&0O(SXM-#RL'MJ#WN!&/D3)D**2 D_L/&##]#\7%,TIY
M23F2D;4[69>R!CT[F>11E1M2()CO@O$!*2/"R&BPJ:A(^2,(YF).[.C1.\,/
MA8V>1_^)D?3Y#DZ96%P<H!'O=!M8@1D^Y8$(3S1H38OM4GK1Y=^*!O_PP*&S
M2ZQW4X+.#D'/O,I*=U1X\-N;03IW4<.Q'N\F3.R'AJL+8O1 .DSZ]<BWA@>H
M7I,"5K27Y?1/>(G*)A2&5>XM@DM]'_5SAM-9YPCI1AJ@60^X:RB#:S@Q\"6Y
MYW9E%!;ZC=I7:2D1Z0X ,J=@FEX$TV9+9")A-JTLEDZ5K,<BD<]Q_EF\RY]P
MIR<O&2VLX%]85C9SFYP348;>DQ.T&^@ F]BT1!!$+I!?R&J#R?SFW8%/HGN8
MB#AYO943E?F#,\@_F;KH_2X49>7;6$O(K \I  75H:#JGPK9*8/Q2K8];SY-
M4S)2 "9^X'.0>;AGBXH/#>%31M /MMY)"1H?@KG]+LSK^+3+@9]IC(:>L1[O
M+N27,CX/".)5\O?#:8#+]1G- %G/) 2Y+:RL/X&\4[V&WC?3K[?RLO$&P^NU
M-*-A/9X1J)UQHN\$EE.>0GO;9(X-Q91[.#YT$$^5<KY]K%>W+TIYN'&B_@B8
MK>/D*"AB$R.HER8JC*%#3Q8867T%+DB"'DBCP98WV2QZT6Q0)%+/JU\.I?@U
M-BTY)@@3I.B"H)TE2O[5MB2)[UC.OXJFM=*99S<;EZB<"=/X*VO6I",<"A_E
MV0 +[P7J_4/F<==17#QU;YBR&AK3AZC'J%/#*$ZDHPEQGA5:A)4:/&]V-"]
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MUG'Y#7W2D6:A%5M='9&=L!N9QY'D$RN26V^ [W:/TZE)="2=0U1D05!'0L:
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MB_JOJ-]EM/H.;W793"_C]%$@I;MAO:!QS3*7TH?C9&3].SJ!&\J9<2=11I<
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10'DB Q8     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139773154111536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 29,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arcus Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3898435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3928 Point Eden Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hayward<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">694-6200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RCUS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001724521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 29,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MCH886CDC!*BA_X0V5<:RA/PMLJ.#M$:Q&[9"+/."<C8(<#_/>W (JZ#C*+A
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M ;Q?*&5?"^X0H#C#&?P 4$L#!!0    ( #5"/EB?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M 5!+ 0(4 Q0    ( #5"/E@'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ -4(^6&KD'Y3N    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ -4(^6)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    "  U0CY8I;B@7'0$  #/$0  &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ -4(^6)^@&_"Q @  X@P   T              ( !MPP  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    "  U0CY8EXJ[',     3 @  "P
M@ &3#P  7W)E;',O+G)E;'-02P$"% ,4    "  U0CY8JL0B%C,!   B @
M#P              @ %\$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M-4(^6"0>FZ*M    ^ $  !H              ( !W!$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ -4(^6&60>9(9 0  SP,  !,
M             ( !P1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  "Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rcus-20240129.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="rcus-20240129.htm">rcus-20240129.htm</File>
    <File>rcus-20240129.xsd</File>
    <File>rcus-20240129_def.xml</File>
    <File>rcus-20240129_lab.xml</File>
    <File>rcus-20240129_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rcus-20240129.htm": {
   "nsprefix": "rcus",
   "nsuri": "http://arcusbio.com/20240129",
   "dts": {
    "inline": {
     "local": [
      "rcus-20240129.htm"
     ]
    },
    "schema": {
     "local": [
      "rcus-20240129.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "rcus-20240129_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "rcus-20240129_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rcus-20240129_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://arcusbio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20240129.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20240129.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001724521-24-000034-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001724521-24-000034-xbrl.zip
M4$L#!!0    ( #5"/ECJLTYD,1H  '2&   )    97@Y.3$N:'1M[5U9=QLW
MLGZ_OP+7GLG8YY ,%RV6Y/@<1;83S75LQU(RRTL.V V2B+H;':!;,O/K;RU
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MNCO;_>[V[E87#X_]C&KS21Z[KPO=8^UW$6OW/W$O#?PWJ_+LV?\#4$L#!!0
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MN#]IO+GB(Q#R,W9++L6(!F_R"C0QJ&S)!Z:AXG^SAEV#6?3/6P/I,8RC:9-
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M?;5JXL>:[1H&6F#% J49'?O/3JQ-%PKLI[<]D==8>FC-0\#_BO'>A>2NR$P
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M/YZUKKY>;O:MW]7YF4PT4-[=J;7%NK^DNF*:$]_@H&5^U0DV#XMS71HK74O
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MI&:@#K\:9V EH9H%=GBQG]KO-2F&)A(/>>:@WP*K#@T%ZL4^$\_5CZWA*M.
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M/XQ;6+NKAADNF$\'"0JCQ$=Q6!!$PB!&>1I@2H#$+ @^S8;^@.8)IA$*PLC
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M_U]X;!C-[SZC_W>DW1H;K^?/),7Y?3QZ=?]&]])]S>KHU?\ 4$L! A0#%
M  @ -4(^6.JS3F0Q&@  =(8   D              ( !     &5X.3DQ+FAT
M;5!+ 0(4 Q0    ( #5"/EAN<%,W/A4  #Z+   1              "  5@:
M  !R8W5S+3(P,C0P,3(Y+FAT;5!+ 0(4 Q0    ( #5"/EC/*>\F= (  &((
M   1              "  <4O  !R8W5S+3(P,C0P,3(Y+GAS9%!+ 0(4 Q0
M   ( #5"/EBS!B!SZ@(  !H+   5              "  6@R  !R8W5S+3(P
M,C0P,3(Y7V1E9BYX;6Q02P$"% ,4    "  U0CY8]K_+I3 +  !'9@  %0
M            @ &%-0  <F-U<RTR,#(T,#$R.5]L86(N>&UL4$L! A0#%
M  @ -4(^6/*X/,I(!P  -C<  !4              ( !Z$   ')C=7,M,C R
C-# Q,CE?<')E+GAM;%!+!08     !@ & 'X!  !C2      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>rcus-20240129_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rcus-20240129.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2024-01-29</startDate>
            <endDate>2024-01-29</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001724521</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-01-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Arcus Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38419</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">47-3898435</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">3928 Point Eden Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Hayward</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94545</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">694-6200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">RCUS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
